Kazuhiko Ikeda Koki Ueda Takahiro Sano Kazuei Ogawa Takayuki Ikezoe Yuko Hashimoto Soji Morishita Norio Komatsu Hitoshi Ohto Yasuchika Takeishi
10.2169/internalmedicine.56.7871
Intern Med
2017;56(13):1705-1710.
jak2 exon 12 mutation myelofibrosis polycythemia vera ruxolitinib thrombocytopenia
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/28674362/
Janus Kinase 2 / genetics Polycythemia Vera / drug therapy Polycythemia Vera / genetics Pyrazoles / therapeutic use
Janus Kinase 2 / genetics Polycythemia Vera / drug therapy Polycythemia Vera / genetics Pyrazoles / therapeutic use Case Reports Aged, 80 and over Exons Humans Janus Kinase 2 / antagonists & inhibitors Male Mutation Nitriles Polycythemia / genetics Polycythemia / physiopathology Primary Myelofibrosis / genetics Primary Myelofibrosis / physiopathology Pyrazoles / pharmacology Pyrimidines Thrombocytopenia / genetics Thrombocytopenia / physiopathology Nitriles Pyrazoles Pyrimidines ruxolitinib Janus Kinase 2
PMC5519475
28674362
The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
2017